Loading cancer entity…
Loading cancer entity…
Clinical trials
58 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (2)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05041127 | Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma | active not recruiting | Phase 2 | 29 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT05286801 | Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors | active not recruiting | Phase 1 / Phase 2 | 86 | National Cancer Institute (NCI)NIH | 3 | Jul 14, 2026 | clinicaltrials |
| NCT04416568 | Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative Cancers | active not recruiting | Phase 2 | 30 | Dana-Farber Cancer InstituteOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT06625190 | Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors | recruiting | Phase 1 / Phase 2 | 27 | University of FloridaOTHER | 1 | Jun 30, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT00496119 | Proton Beam Therapy for Chordoma Patients | active not recruiting | Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT06957327 | A Study of ERAS-601 in People With Chordoma | active not recruiting | Phase 1 / Phase 2 | 12 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT05407441 | Tazemetostat+Nivo/Ipi in INI1-Neg/SMARCA4-Def Tumors | active not recruiting | Phase 1 / Phase 2 | 49 | Susan Chi, MDOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06787664 | A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Chordoma | active not recruiting | Phase 2 | 27 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT02601950 | A Study of Tazemetostat in Adult Participants With Soft Tissue Sarcoma | completed | Phase 2 | 267 | Epizyme, Inc.INDUSTRY | 9 | Jun 22, 2025 | clinicaltrials |
| NCT03647423 | QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma. | withdrawn | Phase 1 / Phase 2 | 0 | ImmunityBio, Inc.INDUSTRY | 1 | Feb 21, 2025 | clinicaltrials |
| NCT03190174 | Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers | completed | Phase 1 / Phase 2 | 34 | Sarcoma Oncology Research Center, LLCOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT03083678 | Afatinib in Locally Advanced and Metastatic Chordoma | completed | Phase 2 | 43 | Leiden University Medical CenterOTHER | 3 | Feb 13, 2025 | clinicaltrials |
| NCT06794645 | Pembrolizumab and Pemetrexed for Progressive Chordoma | recruiting | Phase 2 | 21 | Saint John's Cancer InstituteOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT02383498 | QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma | completed | Phase 2 | 24 | NantCell, Inc.INDUSTRY | 1 | May 20, 2024 | clinicaltrials |
| NCT03623854 | Nivolumab and Relatlimab in Treating Participants With Advanced Chordoma | completed | Phase 2 | 10 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Apr 16, 2024 | clinicaltrials |
| NCT03242382 | Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression.(PalboSarc) | unknown | Phase 2 | 40 | Grupo Espanol de Investigacion en SarcomasOTHER | 1 | Jan 23, 2024 | clinicaltrials |
| NCT01811394 | Ion Irradiation of Sacrococcygeal Chordoma(ISAC) | unknown | Phase 2 | 100 | Heidelberg UniversityOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT06140732 | Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma | unknown | Phase 2 | 30 | Xuanwu Hospital, BeijingOTHER | 1 | Nov 20, 2023 | clinicaltrials |
| NCT03595228 | BN Brachyury and Radiation in Chordoma | completed | Phase 2 | 29 | Bavarian NordicINDUSTRY | 1 | Apr 14, 2023 | clinicaltrials |
| NCT03110744 | CDK4/6 Inhibition in Locally Advanced/Metastatic Chordoma(NCT-PMO-1601) | completed | Phase 2 | 43 | University Hospital HeidelbergOTHER | 1 | Mar 27, 2023 | clinicaltrials |
| NCT04042597 | Anlotinib Hydrochloride Versus Imatinib Mesylate in Locally Advanced, Unresectable or Metastatic Chordoma(CSSG-03) | unknown | Phase 2 | 60 | Peking University People's HospitalOTHER | 1 | Aug 5, 2019 | clinicaltrials |
| NCT00464620 | Trial of Dasatinib in Advanced Sarcomas | completed | Phase 2 | 366 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Nov 23, 2018 | clinicaltrials |
| NCT00592748 | Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine | completed | Phase 1 / Phase 2 | 381 | Massachusetts General HospitalOTHER | 1 | Jun 16, 2017 | clinicaltrials |
| NCT00150072 | Efficacy and Safety of Imatinib in Chordoma | completed | Phase 2 | 55 | Novartis PharmaceuticalsINDUSTRY | 2 | Feb 23, 2017 | clinicaltrials |
Data updated 22 days agoSource updated Sep 4, 2026source: clinicaltrials